Cumulative epidemiological evidence of an association was graded as strong for rs7903146 [odds ratio (OR) = 1.05, p = 4.13 × 10<sup>-5</sup> ] and rs7904519 (OR = 1.07, p = 2.02 × 10<sup>-14</sup> ) in breast cancer, rs11196172 (OR = 1.11, p = 2.22 × 10<sup>-16</sup> ), rs12241008 (OR = 1.13, p = 1.36 × 10<sup>-10</sup> ) and rs10506868 (OR = 1.10, p = 3.98 × 10<sup>-9</sup> ) in colorectal cancer, rs7086803 in lung cancer (OR = 1.30, p = 3.54 × 10<sup>-18</sup> ) and rs11196067 (OR = 1.18, p = 3.59 × 10<sup>-13</sup> ) in glioma, moderate for rs12255372 (OR = 1.12, p = 2.52 × 10<sup>-4</sup> ) in breast cancer and weak for rs7903146 (OR = 1.11, p = 0.007) in colorectal cancer.
The results indicated that the TCF7L2 rs11196172 polymorphism increases the risk of CRC independently, with no evidence of an interaction with diabetes or obesity.
We studied thirteen single nucleotide polymorphisms (SNPs) located in SFRP3 (rs7775), CTNNB1 (β-catenin) [rs4135385, rs13072632], APC (rs454886, rs459552), LRP6 (rs2075241, rs2284396), DKK4 (rs3763511), DKK3 (rs6485350), TCF4 (rs12255372) and AXIN2 (rs3923086, rs3923087, rs4791171) in patients with colorectal cancer (n = 122) and controls (n = 110).
Cumulative epidemiological evidence of an association was graded as strong for rs7903146 [odds ratio (OR) = 1.05, p = 4.13 × 10<sup>-5</sup> ] and rs7904519 (OR = 1.07, p = 2.02 × 10<sup>-14</sup> ) in breast cancer, rs11196172 (OR = 1.11, p = 2.22 × 10<sup>-16</sup> ), rs12241008 (OR = 1.13, p = 1.36 × 10<sup>-10</sup> ) and rs10506868 (OR = 1.10, p = 3.98 × 10<sup>-9</sup> ) in colorectal cancer, rs7086803 in lung cancer (OR = 1.30, p = 3.54 × 10<sup>-18</sup> ) and rs11196067 (OR = 1.18, p = 3.59 × 10<sup>-13</sup> ) in glioma, moderate for rs12255372 (OR = 1.12, p = 2.52 × 10<sup>-4</sup> ) in breast cancer and weak for rs7903146 (OR = 1.11, p = 0.007) in colorectal cancer.
Cumulative epidemiological evidence of an association was graded as strong for rs7903146 [odds ratio (OR) = 1.05, p = 4.13 × 10<sup>-5</sup> ] and rs7904519 (OR = 1.07, p = 2.02 × 10<sup>-14</sup> ) in breast cancer, rs11196172 (OR = 1.11, p = 2.22 × 10<sup>-16</sup> ), rs12241008 (OR = 1.13, p = 1.36 × 10<sup>-10</sup> ) and rs10506868 (OR = 1.10, p = 3.98 × 10<sup>-9</sup> ) in colorectal cancer, rs7086803 in lung cancer (OR = 1.30, p = 3.54 × 10<sup>-18</sup> ) and rs11196067 (OR = 1.18, p = 3.59 × 10<sup>-13</sup> ) in glioma, moderate for rs12255372 (OR = 1.12, p = 2.52 × 10<sup>-4</sup> ) in breast cancer and weak for rs7903146 (OR = 1.11, p = 0.007) in colorectal cancer.
The results demonstrate that patients with the T/T genotype for the rs12255372 polymorphism of the TCF7L2 gene present an increased colorectal cancer risk (OR=2.64, P=0.0236).
Patients carrying the TCF7L2_rs7903146_T allele had an increased risk of CRC (P(trend) = 0.02), whereas patients harboring the IL13_rs20541_T allele had a reduced risk (P(trend) = 0.02).
The T allele of rs7903146 (frequency 30%) was associated with increased risk of colorectal cancer and, more specifically, colon cancer, with adjusted hazard ratios (95% CI) of 1.0 for CC, 1.25 (0.85-1.83) for CT, and 2.15 (1.27-3.64) for TT genotypes (P(trend) = 0.009).
Cumulative epidemiological evidence of an association was graded as strong for rs7903146 [odds ratio (OR) = 1.05, p = 4.13 × 10<sup>-5</sup> ] and rs7904519 (OR = 1.07, p = 2.02 × 10<sup>-14</sup> ) in breast cancer, rs11196172 (OR = 1.11, p = 2.22 × 10<sup>-16</sup> ), rs12241008 (OR = 1.13, p = 1.36 × 10<sup>-10</sup> ) and rs10506868 (OR = 1.10, p = 3.98 × 10<sup>-9</sup> ) in colorectal cancer, rs7086803 in lung cancer (OR = 1.30, p = 3.54 × 10<sup>-18</sup> ) and rs11196067 (OR = 1.18, p = 3.59 × 10<sup>-13</sup> ) in glioma, moderate for rs12255372 (OR = 1.12, p = 2.52 × 10<sup>-4</sup> ) in breast cancer and weak for rs7903146 (OR = 1.11, p = 0.007) in colorectal cancer.